Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Total Non-Current Liabilities (2023 - 2024)

Historic Total Non-Current Liabilities for Contineum Therapeutics (CTNM) over the last 2 years, with Q4 2024 value amounting to $14.8 million.

  • Contineum Therapeutics' Total Non-Current Liabilities rose 16432.4% to $14.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $14.8 million, marking a year-over-year increase of 16432.4%. This contributed to the annual value of $14.8 million for FY2024, which is 16432.4% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Total Non-Current Liabilities of $14.8 million as of Q4 2024, which was up 16432.4% from $5.8 million recorded in Q3 2024.
  • In the past 5 years, Contineum Therapeutics' Total Non-Current Liabilities registered a high of $14.8 million during Q4 2024, and its lowest value of $3.9 million during Q2 2024.